Form 4: Oruka Therapeutics GC Awarded Equity and Options

Oruka Therapeutics General Counsel Paul T. Quinlan received a grant of 32,500 common shares and 130,000 employee stock options.

Summary

• Paul T. Quinlan, General Counsel of Oruka Therapeutics, Inc. (ORKA), acquired 32,500 shares of common stock on January 23, 2026.
• The common stock grant vests as to 1/16 of the shares on each March 14, June 14, September 14, and December 14 (or the immediately preceding trading day if not a trading day).
• Mr. Quinlan also acquired 130,000 employee stock options on January 23, 2026, with an exercise price of $34.39 per share.
• The options have an expiration date of January 22, 2036.
• The employee stock options vest as to 1/48 of the underlying shares monthly, commencing from January 1, 2026.

Sentiment

Score: 6

Explanation: The filing indicates routine equity compensation for a key executive, aligning management incentives with shareholder interests, which is generally viewed positively as it promotes long-term commitment and performance.

Positives

• The equity and option grants align the General Counsel's financial interests with those of the shareholders, promoting long-term value creation.
• Equity compensation is a standard practice for retaining and incentivizing key executives.

Future Outlook

The grants include specific vesting schedules for both common stock and employee stock options, indicating a long-term incentive structure for the General Counsel. The common stock vests quarterly, and the options vest monthly over a four-year period.

Industry Context

Equity compensation, including stock grants and options, is a common practice across industries, particularly in the biotechnology and pharmaceutical sectors, to attract, retain, and motivate key executives. These awards are designed to align executive performance with shareholder value over multi-year periods.

Comparison to Industry Standards

• The vesting schedules (quarterly for stock, monthly over 4 years for options) are typical for executive compensation packages in the biotech industry, aiming to ensure long-term commitment and performance.
• The grant of both restricted stock and stock options is a common dual-incentive approach, providing immediate equity exposure while also offering upside potential through options.

Stakeholder Impact

• Shareholders: The equity awards align the General Counsel's interests with shareholders, potentially leading to better long-term decision-making and value creation.
• Employees: This compensation structure may serve as a benchmark or incentive for other key employees, influencing overall compensation strategy.

Next Steps

• Continued vesting of 1/16 of the common stock shares on each March 14, June 14, September 14, and December 14.
• Continued monthly vesting of 1/48 of the underlying shares for the employee stock options from January 1, 2026.

Key Dates

Keywords

Oruka Therapeutics, ORKA, Paul T. Quinlan, General Counsel, Stock Grant, Stock Options, Equity Compensation, Insider Transaction, SEC Form 4, Vesting Schedule